Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating In Vitro Specification, and In Vivo Scrutinization

PURPOSE: The current investigation is on the explicit development and evaluation of nanostructured lipidic carriers (NLCs) through the oral route to overcome the inherent lacuna of chemotherapeutic drug, in which Ribociclib (RBO) was used for breast cancer to diminish the bioavailability issue. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartaj, Ali, Annu, Biswas, Largee, Verma, Anita Kamra, Sahoo, P. K., Baboota, Sanjula, Ali, Javed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831049/
https://www.ncbi.nlm.nih.gov/pubmed/35155677
http://dx.doi.org/10.1155/2022/6009309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831049/
https://www.ncbi.nlm.nih.gov/pubmed/35155677
http://dx.doi.org/10.1155/2022/6009309

Ejemplares similares